Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.77B |
| 2 |
McKesson
MCK
|
+$2.38B |
| 3 |
SpaceX
SPCX
|
+$2.3B |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$2.05B |
| 5 |
Amazon
AMZN
|
+$1.37B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.96B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$3.11B |
| 3 |
Honeywell
HON
|
+$1.96B |
| 4 |
Salesforce
CRM
|
+$1.47B |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$775M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.02% |
| 2 | Technology | 24.63% |
| 3 | Financials | 9.78% |
| 4 | Healthcare | 7.32% |
| 5 | Industrials | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
6101
Schwab Crypto Thematic Natural Language Processing ETF
STCE
$204M
| $99.5K | ﹤0.01% |
1,422
+1,421
| +142,100% | +$100K |
2024 Q2
8 quarters
|
|
6102
ProMIS Neurosciences
PMN
$84.7M
| $99.5K | ﹤0.01% |
+7,559
| New | +$82.1K |
2026 Q2
0 quarters
|
|
6103
CoinShares PLC
CSHR
$584M
| $99.3K | ﹤0.01% |
+26,336
| New | +$139K |
2026 Q2
0 quarters
|
|
6104
FT Vest US Equity Enhance & Moderate Buffer ETF December
XDEC
$209M
| $99.2K | ﹤0.01% |
2,316
| – | – |
2024 Q3
7 quarters
|
|
6105
Anbio Biotechnology
NNNN
$194M
| $99.1K | ﹤0.01% |
7,231
-107
| -1% | -$2.68K |
2025 Q2
4 quarters
|
|
6106
AB New York Intermediate Municipal ETF
NYM
$1.27B
| $99K | ﹤0.01% |
3,940
-9
| -0.2% | -$225 |
2025 Q4
2 quarters
|
|
6107
American Century Large Cap Equity ETF
ACLC
$336M
| $98.7K | ﹤0.01% |
1,173
| – | – |
2024 Q4
6 quarters
|
|
6108
FT Vest Gold Strategy Target Income ETF
IGLD
$588M
| $98.5K | ﹤0.01% |
4,678
+81
| +2% | +$1.93K |
2024 Q3
7 quarters
|
|
6109
ImageneBio Inc
IMA
$48.2M
| $98.4K | ﹤0.01% |
16,678
-1,661
| -9% | -$9.38K |
2021 Q2
20 quarters
|
|
6110
Inseego
INSG
$75.6M
| $98.1K | ﹤0.01% |
9,492
-17,549
| -65% | -$235K |
2013 Q2
52 quarters
|
|
6111
US Diversified Real Estate ETF
PPTY
$23.8M
| $98K | ﹤0.01% |
2,860
-250
| -8% | -$8.18K |
2025 Q3
3 quarters
|
|
6112
Motley Fool Small-Cap Growth ETF
TMFS
$51.9M
| $98K | ﹤0.01% |
2,711
-75
| -3% | -$2.57K |
2019 Q2
28 quarters
|
|
6113
OFS Capital
OFS
$54.8M
| $97.6K | ﹤0.01% |
27,562
-12,001
| -30% | -$43.9K |
2013 Q4
50 quarters
|
|
6114
CP High Yield Trend ETF
HYTR
$297M
| $97.4K | ﹤0.01% |
4,559
+1,298
| +40% | +$27.8K |
2025 Q3
3 quarters
|
|
6115
Maui Land & Pineapple Co
MLP
$303M
| $97.3K | ﹤0.01% |
5,471
-2,710
| -33% | -$44.9K |
2013 Q4
50 quarters
|
|
6116
Harbor Dividend Growth Leaders ETF
GDIV
$235M
| $97.1K | ﹤0.01% |
5,266
-223
| -4% | -$4.03K |
2024 Q2
8 quarters
|
|
6117
Overlay Shares Large Cap Equity ETF
OVL
$491M
| $97.1K | ﹤0.01% |
1,715
-85
| -5% | -$4.74K |
2020 Q3
23 quarters
|
|
6118
ProShares Ultra Semiconductors
USD
$2.79B
| $96.1K | ﹤0.01% |
921
+475
| +107% | +$41.3K |
2018 Q2
32 quarters
|
|
6119
Seres Therapeutics
MCRB
$26.9M
| $95.8K | ﹤0.01% |
12,138
-9,562
| -44% | -$72.8K |
2015 Q2
44 quarters
|
|
6120
Equillium
EQ
$95.1M
| $95.6K | ﹤0.01% |
29,887
+11,367
| +61% | +$27.2K |
2024 Q4
6 quarters
|
|
6121
ClearBridge Dividend Strategy ESG ETF
YLDE
$176M
| $95.2K | ﹤0.01% |
1,712
| – | – |
2023 Q3
11 quarters
|
|
6122
Columbia Research Enhanced Value ETF
REVS
$371M
| $94.9K | ﹤0.01% |
3,019
| – | – |
2022 Q2
16 quarters
|
|
6123
Goldman Sachs Small Cap Equity ETF
GSC
$278M
| $94.6K | ﹤0.01% |
1,366
-864
| -39% | -$53.2K |
2025 Q1
5 quarters
|
|
6124
Canton Strategic Holdings
CNTN
$168M
| $94.3K | ﹤0.01% |
33,449
+13,687
| +69% | +$43.3K |
2025 Q4
2 quarters
|
|
6125
Century Therapeutics
IPSC
$261M
| $94.2K | ﹤0.01% |
38,454
+12,205
| +46% | +$27.9K |
2026 Q1
1 quarter
|
|
Similar funds
Morgan Stanley's Q2 2026 Portfolio in Review
As of Q2 2026, Morgan Stanley held 8,715 positions worth $1.89T, up 14% from $1.66T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Morgan Stanley's Q2 2026 filing shows 425 new, 3,807 increased, 3,215 reduced and 303 closed positions. Its largest new stake was SpaceX: 13,532,773 shares worth $2.31B. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.96B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q2 2026 buy was SpaceX: 13,532,773 shares worth $2.31B.
- Morgan Stanley added most to NVIDIA in Q2 2026, an estimated $2.77B increase.
- Morgan Stanley's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.96B.
- Morgan Stanley fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $404M.
- Morgan Stanley's ten largest holdings make up 21% of its $1.89T portfolio in Q2 2026.
- Morgan Stanley opened 425 new positions and closed 303 in Q2 2026.
- Morgan Stanley's portfolio value rose 14% quarter-over-quarter to $1.89T.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.